Deferoxamine Mesylate: Mechanistic Leverage and Translati...
2025-10-18
Explore how Deferoxamine mesylate, a premier iron-chelating agent, uniquely modulates ferroptosis, hypoxia signaling, and tumor microenvironment dynamics. With a mechanistic lens and strategic guidance, this article empowers translational researchers to harness iron homeostasis as both a tool and target in experimental and preclinical settings—escalating beyond conventional product overviews.